Answer
Ublituximab selectively binds CD20 on B cells, inducing their destruction primarily through antibody-dependent cell-mediated cytotoxicity and, to a lesser extent, complement-dependent cytotoxicity.
Sources for this answer
- Briumvi 150 mg concentrate for solution for infusionNeuraxpharm UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 2Document updated
Sources checked